Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

XORTX Therapeutics Inc. XRTX NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • CA • USD

SharesGrow Score
49/100
2/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

XORTX Therapeutics Inc. (XRTX) is a Biotechnology company in the Healthcare sector, currently trading at $2.16. It has a SharesGrow Score of 46/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Valuation: XRTX trades at a trailing Price-to-Earnings (P/E) of -0.2 (S&P 500 average ~25).

Net income is $4M (loss), growing at -7.8%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $51,111 against $3M equity (Debt-to-Equity (D/E) ratio 0.02, conservative). Current ratio is 1.61 (strong liquidity). Debt-to-assets is 1.4%. Total assets: $4M.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future ?/100 (Fail), Income ?/100 (Fail).

XRTX SharesGrow Score Overview

61/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — XRTX

✓
VALUE Pass
100/100
XRTX trades at a trailing Price-to-Earnings (P/E) of -0.2 (S&P 500 average ~25). Trailing PEG 0.01. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
XRTX: +0%/yr revenue is, -7.8%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet XRTX: Debt-to-Equity (D/E) ratio 0.02 (conservative), Current ratio is 1.61 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
XRTX: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.37-7.05
Volume39.89K
Avg Volume (30D)58.97K
Market Cap$601.54K
Beta (1Y)0.09
Share Statistics
EPS (TTM)-3.90
Shares Outstanding$946.93K
IPO Date2021-09-23
Employees2
CEOAllen Warren Davidoff
Financial Highlights & Ratios
Gross Profit$-156.66K
EBITDA$-4.39M
Net Income$-3.71M
Operating Income$-4.55M
Total Cash$1.19M
Total Debt$51.11K
Net Debt$-1.13M
Total Assets$3.68M
Price / Earnings (P/E)-0.6
Analyst Forecast
Company Info
CountryCA
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINCA98420Q3061

Price Chart

Track all markets on TradingView
XRTX
XORTX Therapeutics Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
0.37 52WK RANGE 7.05

People Also View

CNTX
CNTX
Context Therapeutics Inc.
$2.51
-0.60%
 NRSN
NRSN
NeuroSense Therapeutics Ltd.
$0.73
+2.82%
 ENSC
ENSC
Ensysce Biosciences, Inc.
$0.54
+2.90%
 QNRX
QNRX
Quoin Pharmaceuticals, Ltd.
$6.49
+3.02%
 BTTX
BTTX
Better Therapeutics, Inc.
$0.00
+0.00%
 LLY
LLY
Eli Lilly and Company
$905.13
-1.88%
 JNJ
JNJ
Johnson & Johnson
$238.67
-0.60%
 ABBV
ABBV
AbbVie Inc.
$208.43
-0.87%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message